Sex | Treatment groupse |
---|
V/Va | V/INSb | Lz/Vc | Lz/INSd |
---|
Male | 174.5 ± 11.1 | 75.3 ± 4.1* | 182.3 ± 8.9 | 72.8 ± 2.3* |
Female | 169.7 ± 5.9 | 60.3 ± 3.8* | 148.2 ± 7.1*** | 79.5 ± 4.5** |
- a Intracerebroventricular (icv) V infusion days 5–11; subcutaneous (sc) V injection day 11
- b icv V infusion days 5–11; sc neutral protamine Hagedorn insulin (INS; 10 U/kg bw) day 11
- c icv letrozole (Lz; 1.67 µg/µL dosage, 0.5 µL/h infusion rate) infusion days 5–11; sc V injection day 11
- d icv Lz infusion days 5–11; sc INS injection day 11
- e F(7/40) = 68.61; p < 0.0001
- * p < 0.0001 versus V-injected controls
- ** p < 0.005 versus V-injected controls
- *** p < 0.001 Lz/V-M versus Lz/V-F